Plasmatic Levels of HSP90α at Diagnosis: A Novel Prognostic Indicator of Clinical Outcome in Advanced Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors Plus Chemotherapy

Overview of attention for article published in Frontiers in oncology, December 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 15 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 7,494 followers.

New article: Plasmatic Levels of HSP90alpha at Diagnosis: A Novel Prognostic Indicator of Clinical Outcome in Advanced Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors Plus Chemotherapy https://t.co/bxpA2D6m91 #lungcancer #oncology https://t.co/OH0G

20 Dec 2021

Reply Repost Favourite

RT @FrontOncology: New research: Plasmatic Levels of HSP90α at Diagnosis: A Novel Prognostic Indicator of Clinical Outcome in Advanced Lung…

04 Dec 2021

Reply Repost Favourite

New research: Plasmatic Levels of HSP90α at Diagnosis: A Novel Prognostic Indicator of Clinical Outcome in Advanced Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors Plus Chemotherapy: Background The purpose of this study was set to… https://t.co/WGD

03 Dec 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.